RTTNews BiotechCodex · 实盘不做把握 5/10不做原因:已被定价
北京时间·🕒 发布 21:38:03·⟳ 抓取 21:45:14 +7m11s·⚡ 决策 09-08 23:52:22 +2h07m·48.9 天前
Adlai Nortye 获 FDA 放行 AN4035 Phase I 并在澳洲完成首例给药
这是正向临床执行消息，但公司在 8/3 和 8/14 已先披露 AN4035 在澳洲获批、IND 进程推进和 2H26 首例给药预期；今天只是把预期落地为首例入组并拿到 FDA 放行，边际增量有限。盘中股价仅温和上行，说明市场已在做部分重定价，当前缺少足够的预期差支持追价。
📄 原文RTTNews Biotech↗ 原文
Adlai Nortye Receives FDA Clearance For AN4035 Phase I Trial
Adlai Nortye Group Ltd. (ANL) announced that the first patient has been dosed in Australia in its global Phase I trial…
不做 Adlai Nortye Group Ltd.（ANL.US）
这是正向临床执行消息，但 8/3 和 8/14 已先预告澳洲审批与首例给药节奏，今天新增信息更像确认而非新商业价值释放；盘中仅温和上行，边际预期差不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事实是 AN4035 首例给药+FDA 放行，方向偏正；但同一项目此前已被公司公告预热，今天新增信息更像执行确认而非新商业价值释放。对临床阶段 biotech，这类里程碑通常只能带来有限短线反应，且当前盘中涨幅不大，说明 edge 偏薄，因此不做。
消息传播链
- 公司最早正式披露 AN4035 已在澳洲首例给药，并收到 FDA Study-May-Proceed 信函。市场反应:盘前/盘中对 ANL 构成温和正反应预期。
- SEC 6-K 把同一新闻作为正式披露文件挂出，确认事件属公司级一手公告。
- 媒体在数小时后扩散同一条临床/监管进展，说明信息开始进入更广泛交易视野。市场反应:报道时 ANL 约 15.49 美元，日内约涨 2.49%。
关键理由
- AN4035 首例给药和 FDA 放行确认项目已进入早期临床，属于管线推进的正面信号。
- AN4035 面向 CEACAM5 富集、RAS 依赖肿瘤，若后续人体数据成立，平台想象空间不小。
- 但当前没有疗效数据、金额和收入贡献，且前序公告已部分定价。
主要风险
- 这是纯临床前段执行，不是数据读出或商业化，后续失败概率仍高。
- 事件已被 8 月公告部分预告，短线更容易变成确认而非重新定价。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-14 · 影响 weakens
8/14 公司已提前披露澳洲监管批准、2H26 首例给药预期和 2H27 初始数据，今天的核心信息不算完全新鲜。
检索:Adlai Nortye AN4035 first regulatory approval expected first patient dosed 2H26 August 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-09-08 · 影响 weakens
盘中报价仅约 15.30 美元、较前收涨约 2%，说明市场在温和重定价而非剧烈重估。
检索:ANL intraday price Sept 8 2026 Adlai Nortye FDA clearance first patient dosed 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例支持方向为正，但同时压低仓位与买点期望；本次更适合等后续人体数据，而不是把今天的执行确认当成新一轮主升催化。
方向:同类早期临床/IND 事件通常偏正，但更多体现为温和短线反应，而不是足以支撑高置信追价。
涨幅量级:高相似可比里，较干净的样本多在个位数上涨；只有更强的题材或更大监管跃迁才会出现大幅跳升。
形态:首例给药/IND 放行经常先涨后分化，见光回吐并不少见。
历史先例(按相似度)
- 相似度 7/10 BLRX.US 2026-05-27 BioLineRx 首例给药后盘前涨约 4.4%。 原文 ↗
事件后 +1日 +4.2% · +2日 +11.1% · +3日 +16.9% · +4日 +7.7% · +5日 +4.9%
⚠非首发(转载/聚合)·来源层级不符(声明wire/实为aggregator)·锚前1-2日已异动10.5%>锚定日4.2% — 该行涨幅别用来定止盈止损
相似度依据:同为美股小型 biotech 的首例给药/临床推进，都是早期管线执行事件，但 BLRX 还叠加财报。
经验:这类里程碑常有正面反应，但多为个位数涨幅，难支持激进追价。 - 相似度 7/10 PRLD.US 2026-02-03 Prelude Therapeutics 获 FDA 早期试验放行后，盘前涨约 6.85%。 原文 ↗
事件后 +1日 +0.4% · +2日 -11.8% · +3日 -5.2% · +4日 -5.9% · +5日 -8.3%
⚠来源层级不符(声明wire/实为media)·锚前1-2日已异动23.8%>锚定日0.4% — 该行涨幅别用来定止盈止损
相似度依据:同为 FDA 放行早期临床/IND 的生物科技事件，机制接近但不含首例给药。
经验:IND 放行通常给短线正反应，但若只是程序性放行，幅度有限。 - 相似度 6/10 SER.US 2026-01-28 Serina Therapeutics 获 IND clearance 后盘后大涨约 30%。 原文 ↗
事件后 +1日 +30.1% · +2日 +19.5% · +3日 +0.0% · +4日 +1.5% · +5日 +4.4%
⚠非首发(转载/聚合)·来源层级不符(声明media/实为aggregator) — 该行涨幅别用来定止盈止损
相似度依据:同为 FDA IND clearance，但属于神经系统项目，且有更强的题材属性。
经验:IND 通过可触发明显上涨，但是否持续取决于项目热度和后续数据，而非审批本身。 - 相似度 6/10 AAPG.US 2026-01-06 Ascentage 获 FDA IND clearance，属于 pipeline 扩展。 原文 ↗
事件后 +1日 -3.5% · +2日 +4.7% · +3日 +3.5% · +4日 +6.8% · +5日 +5.3%
相似度依据:同为 FDA IND clearance 的肿瘤早期研发事件，但缺少公开即时报价反应。
经验:程序性监管放行本身不足以保证持续重估，常需要后续人体数据接力。
工具执行结果 · 成功 6 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 2,916 字
Adlai Nortye Group Ltd. (ANL) announced that the first patient has been dosed in Australia in its global Phase I trial evaluating AN4035, a first-in-class CEACAM5-targeting antibody-drug conjugate (ADC) armed with a pan-RAS(ON) inhibitor payload.
The company also received a "Study-May-Proceed" letter from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application, clearing the path to expand the Phase I trial into the United States.
The trial is evaluating AN4035 in patients with CEACAM5-enriched, RAS-addicted solid tumors.
The study will assess the candidate's safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy as a monotherapy and in combination with cetuximab.
CEACAM5 is highly overexpressed in colorectal, pancreatic and lung cancers, which frequently harbor RAS mutations.
AN4035 is designed to deliver a highly potent pan-RAS(ON) inhibitor directly to CEACAM5-positive tumor cells.
The company said the approach is intended to provide tumor-selective RAS pathway inhibition while potentially reducing the on-target, off-tumor toxicities associated with systemic pan-RAS(ON) inhibitors.
AN4035 is the first proof-of-concept candidate from Adlai Nortye's proprietary RAS Inhibitor Conjugated Antibody (RASiCA) platform.
In preclinical studies, AN4035 demonstrated favorable thermal and plasma stability, desirable pharmacokinetic properties and strong intracellular payload retention.
The candidate showed nanomolar to picomolar cytotoxicity in CEACAM5-positive, RAS-addicted cancer cell lines, along with a potent bystander-killing effect.
The ADC also demonstrated robust anti-tumor activity and deep tumor regression in CEACAM5-positive cell-derived xenograft and patient-derived xenograft models.
Compared with the unconjugated payload, AN4035 showed enhanced tumor retention and improved tumor selectivity over normal tissues.
Adlai Nortye said it is on track to report full Phase Ia data in the second half of 2027.
The company is also preparing an IND application for AN4035 with China's National Medical Products Administration (NMPA).
Adlai Nortye is developing cancer therapies across two key areas: precision RAS pathway-targeted therapies, including the oral pan-RAS(ON) inhibitor AN9025 and AN4035, and next-generation PD-1/L1 pathway-modulating immunotherapies, including the multifunctional fusion protein AN8025.
Currently, ANL shares are trading at $15.49, up 2.49%.
For comments and feedback contact: editorial@rttnews.com
Business News
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.
The company also received a "Study-May-Proceed" letter from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application, clearing the path to expand the Phase I trial into the United States.
The trial is evaluating AN4035 in patients with CEACAM5-enriched, RAS-addicted solid tumors.
The study will assess the candidate's safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy as a monotherapy and in combination with cetuximab.
CEACAM5 is highly overexpressed in colorectal, pancreatic and lung cancers, which frequently harbor RAS mutations.
AN4035 is designed to deliver a highly potent pan-RAS(ON) inhibitor directly to CEACAM5-positive tumor cells.
The company said the approach is intended to provide tumor-selective RAS pathway inhibition while potentially reducing the on-target, off-tumor toxicities associated with systemic pan-RAS(ON) inhibitors.
AN4035 is the first proof-of-concept candidate from Adlai Nortye's proprietary RAS Inhibitor Conjugated Antibody (RASiCA) platform.
In preclinical studies, AN4035 demonstrated favorable thermal and plasma stability, desirable pharmacokinetic properties and strong intracellular payload retention.
The candidate showed nanomolar to picomolar cytotoxicity in CEACAM5-positive, RAS-addicted cancer cell lines, along with a potent bystander-killing effect.
The ADC also demonstrated robust anti-tumor activity and deep tumor regression in CEACAM5-positive cell-derived xenograft and patient-derived xenograft models.
Compared with the unconjugated payload, AN4035 showed enhanced tumor retention and improved tumor selectivity over normal tissues.
Adlai Nortye said it is on track to report full Phase Ia data in the second half of 2027.
The company is also preparing an IND application for AN4035 with China's National Medical Products Administration (NMPA).
Adlai Nortye is developing cancer therapies across two key areas: precision RAS pathway-targeted therapies, including the oral pan-RAS(ON) inhibitor AN9025 and AN4035, and next-generation PD-1/L1 pathway-modulating immunotherapies, including the multifunctional fusion protein AN8025.
Currently, ANL shares are trading at $15.49, up 2.49%.
For comments and feedback contact: editorial@rttnews.com
Business News
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。